Skip to main content

Expression of Toll‐like receptor9 in diffuse large B‐cell lymphoma: further exploring CpG oligodeoxynucleotide in NFκB pathway

Buy Article:

$51.00 plus tax (Refund Policy)

Abstract:

Human Toll‐like receptors (TLRs) that recognize a variety of pathogen‐associated molecular patterns are associated with activation and immunogenic response in lymphoid neoplasms, but rarely explored in diffuse large B‐cell lymphoma (DLBCL). We conducted this study to evaluate the expression of TLR9 in and potential treatment of DLBCL with TLR9 agonist – CpG oligodeoxynucleotide (ODN). The real‐time quantitative reverse transcription‐polymerase chain reaction was carried out to detect TLR9 expression in 41 formalin‐fixed paraffin‐embedded samples. The transformation of immunophenotype and NFκB pathway of DLBCL upon CpG ODN stimulation were investigated by a DLBCL cell line. TLR9 was commonly detected in DLBCL with relative mRNA levels above 1.0 × 10−2 in 35 of 41 cases (85.36%). It was suspected that a high proportion of DLBCL to be activated by CpG stimulation. In vitro study with a DLBCL cell line revealed an increased CD20, but decreased BCL‐6 and MUM1/IRF4 expression after treatment with CpG ODN. The NFκB pathway was initially activated, but finally suppressed upon CpG ODN stimulation. The proliferation of tumor cells was also inhibited by long time incubation. These findings provide new insights into the role of TLR9 in DLBCL and potential implication of TLR9 agonist in the treatment of DLBCL.

Document Type: Research Article

DOI: http://dx.doi.org/10.1111/j.1600-0463.2012.02915.x

Publication date: November 1, 2012

mksg/apm/2012/00000120/00000011/art00002
dcterms_title,dcterms_description,pub_keyword
6
5
20
40
5

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more